TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial. The goal is to improve the engraftment of auto islet cell transplantation (AICT) in patients with severe, chronic pancreatitis. BRI has developed a therapy for treatment of chronic pancreatitis and TikoMed believes its product can enhance the outcome of the treatment by improving the survival of transplanted cells by inhibiting a destructive immunological reaction (IBMIR) and through stimulation of growth factors.

This BRI study "Attenuating Instant Blood-Mediated Inflammatory Reaction in Autologous Islet Transplantation" is a Phase II, single center study, with the objective of documenting efficacy, safety and tolerability of IBsolvMIR in auto islet transplants for patients with chronic pancreatitis. The study will be conducted at BRI under the direction of Marlon F. Levy, MD, principal investigator.

"The Baylor islet transplantation team is looking forward to working with TikoMed to try to better the lives of patients who undergo auto islet cell transplantation," Dr. Levy said.

"Since TikoMed is dedicated to improve treatment of severe and life threatening diseases it is very inspiring to work with BRI. Building a long-term relationships between Sweden and world leading institutions, such as Baylor, is of great importance making it possible to establish better treatments for severe diseases," said Adam Bruce, TikoMed chairman.

Added Anders Waas, TikoMed CEO, "Entering into a phase II study in the US is a significant step in the clinical development of IBsolvMIR. It strengthens TikoMed's competitive position in partnership discussions and for commercialization for IBsolvMIR in the US."